January 10, 2019
Tokyo Medical and Dental University said on January 9 that its research group will commence an investigator-initiated clinical study of Novartis Pharma’s JAK1/2 inhibitor Jakavi (ruxolitinib) in patients with chronic active Epstein-Barr virus infection (CAEBV). CAEBV is a rare disease...read more